We also evaluated the levels of COL5A1 in gliomas according to their isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion status, which served as important molecular markers for identifying glioma subtypes. This evidence concerns the gene COL5A1 and central nervous system cancer.